Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)

Monday, May 19, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

RESEARCH TRIANGLE PARK, N.C. and TORONTO, May 18 Patients with both asthma and allergic rhinitis, or seasonal allergies,experience significantly better lung function when treated with AdvairDiskus(R) (fluticasone propionate and salmeterol inhalation powder) ascompared with Singulair (montelukast sodium). The results of the 660-subjectstudy were presented today at the International Conference of the AmericanThoracic Society meeting in Toronto.

The study also showed patients treated with Advair plus Singulair saw nomeasurable improvement compared to patients treated with Advair alone in theirasthma symptoms or albuterol use. In another comparison patients using Advairplus the intranasal corticosteroid, fluticasone propionate nasal spray, sawsignificant improvement in daytime nasal symptoms compared to patients treatedwith Advair plus Singulair (p<0.001).

"These findings give us a greater understanding of how to treat patientswith asthma and seasonal allergies, two diseases that often are seen intandem," said Rohit Katial, MD, National Jewish Medical Research Center. "Byusing the right combination of treatments, physicians can help patients gainrelief from the symptoms of both diseases."

The study included people age 15 and up who had both persistent asthma andseasonal allergies. Patients received one of four different treatments: AdvairDiskus 100/50 twice daily, Singulair 10 mg once daily, Advair 100/50 twicedaily with Singulair 10 mg once daily or Advair 100/50 twice daily withfluticasone propionate nasal spray 200 mcg once daily. Those who receivedAdvair alone had significant improvements in their morning peak expiratoryflow, a measure of asthma control, as compared with Singulair alone (p<0.001).Secondary endpoints, including symptom-free days and rescue-treatment-freedays, were significantly increased in the Advair group compared with theSingulair group. The incidence of adverse events was similar among all groups.

Advair Diskus combines two medications in one device to help prevent andcontrol asthma symptoms. Asthma causes inflammation (swelling in the airways)and airway constriction (the tightening of muscles that surround the airways),and Advair contains both an inhaled corticosteroid, fluticasone propionate, toreduce inflammation; and an inhaled long-acting bronchodilator, salmeterol, tohelp prevent and reduce airway constriction. Advair is for people who stillhave symptoms on another asthma controller, or whose disease severity clearlywarrants treatment with two maintenance therapies.

Important Information about Advair

Advair won't replace fast-acting inhalers for sudden symptoms and shouldnot be taken more than twice a day. Advair contains salmeterol. In patientswith asthma, medicines like salmeterol may increase the chance of asthma-related death. So Advair is not for people whose asthma is well controlled onanother controller medicine. People should speak to their doctor about therisks and benefits of treating their asthma with Advair. People taking Advairshould see their doctor if their asthma does not improve. Thrush in the mouthand throat may occur. People should tell their doctor if they have a heartcondition or high blood pressure. Some people may experience increased bloodpressure, heart rate, or changes in heart rhythm. Advair Diskus is forpatients 4 years and older. For patients 4 to 11 years old, Advair Diskus100/50 is for those who have asthma symptoms while on an inhaledcorticosteroid. Advair HFA is for patients 12 years and older.

For more information about Advair please visit

Important Information about Flonase

For best results, use Flonase daily. Your nasal symptoms may begin toimprove in as few as 12 hours. Maximum relief may take several days. Resultsmay vary. If side effects, they are generally mild and may include headache,nosebleed, or

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store